An update on diagnostic options and considerations in limb-girdle dystrophies

Corrado Angelini, Laura Giaretta, Roberta Marozzo

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: Limb-girdle muscular dystrophies (LGMDs) encompass a clinically heterogeneous group of rare, genetic progressive muscle disorders presenting with weakness and atrophy of predominant pelvic and shoulder muscles. The spectrum of disease severity ranges from severe childhood-onset muscular dystrophy to adult-onset dystrophy. Areas covered: The review presents an update of the clinical phenotypes and diagnostic options for LGMD including both dominant and recessive LGMD and consider their differential clinical and histopathological features. An overview of most common phenotypes and of possible complications is given. The management of the main clinical respiratory, cardiac, and central nervous system complications are covered. The instrumental, muscle imaging, and laboratory exams to assess and reach diagnosis are described. The use of recent genetic techniques such as next generation sequencing (NGS), whole-exome sequencing compared to other techniques (e.g. DNA sequencing, protein analysis) is covered. Currently available drugs or gene therapy and rehabilitation management are focused on. Expert commentary: Many LGMD cases, which for a long time previously remained without a molecular diagnosis, can now be investigated by NGS. Gene mutation analysis is always required to obtain a certain molecular diagnosis, fundamental to select homogeneous group of patients for future pharmaceutical and gene trials.

Original languageEnglish
Pages (from-to)693-703
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 2 2018

Fingerprint

Limb-Girdle Muscular Dystrophies
Extremities
Exome
Phenotype
Genetic Techniques
Muscles
Muscular Dystrophies
Muscular Diseases
DNA Sequence Analysis
Genetic Therapy
Genes
Atrophy
Rehabilitation
Central Nervous System
Drug Therapy
Mutation
Pharmaceutical Preparations
Proteins

Keywords

  • calpainopathy
  • dysferlinopathy
  • Limb-girdle muscular dystrophy
  • sarcoglycanopathy
  • transportinopathy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

An update on diagnostic options and considerations in limb-girdle dystrophies. / Angelini, Corrado; Giaretta, Laura; Marozzo, Roberta.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 9, 02.09.2018, p. 693-703.

Research output: Contribution to journalReview article

@article{7e7a3c8bb9e847d18a31e9b92055eca2,
title = "An update on diagnostic options and considerations in limb-girdle dystrophies",
abstract = "Introduction: Limb-girdle muscular dystrophies (LGMDs) encompass a clinically heterogeneous group of rare, genetic progressive muscle disorders presenting with weakness and atrophy of predominant pelvic and shoulder muscles. The spectrum of disease severity ranges from severe childhood-onset muscular dystrophy to adult-onset dystrophy. Areas covered: The review presents an update of the clinical phenotypes and diagnostic options for LGMD including both dominant and recessive LGMD and consider their differential clinical and histopathological features. An overview of most common phenotypes and of possible complications is given. The management of the main clinical respiratory, cardiac, and central nervous system complications are covered. The instrumental, muscle imaging, and laboratory exams to assess and reach diagnosis are described. The use of recent genetic techniques such as next generation sequencing (NGS), whole-exome sequencing compared to other techniques (e.g. DNA sequencing, protein analysis) is covered. Currently available drugs or gene therapy and rehabilitation management are focused on. Expert commentary: Many LGMD cases, which for a long time previously remained without a molecular diagnosis, can now be investigated by NGS. Gene mutation analysis is always required to obtain a certain molecular diagnosis, fundamental to select homogeneous group of patients for future pharmaceutical and gene trials.",
keywords = "calpainopathy, dysferlinopathy, Limb-girdle muscular dystrophy, sarcoglycanopathy, transportinopathy",
author = "Corrado Angelini and Laura Giaretta and Roberta Marozzo",
year = "2018",
month = "9",
day = "2",
doi = "10.1080/14737175.2018.1508997",
language = "English",
volume = "18",
pages = "693--703",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - An update on diagnostic options and considerations in limb-girdle dystrophies

AU - Angelini, Corrado

AU - Giaretta, Laura

AU - Marozzo, Roberta

PY - 2018/9/2

Y1 - 2018/9/2

N2 - Introduction: Limb-girdle muscular dystrophies (LGMDs) encompass a clinically heterogeneous group of rare, genetic progressive muscle disorders presenting with weakness and atrophy of predominant pelvic and shoulder muscles. The spectrum of disease severity ranges from severe childhood-onset muscular dystrophy to adult-onset dystrophy. Areas covered: The review presents an update of the clinical phenotypes and diagnostic options for LGMD including both dominant and recessive LGMD and consider their differential clinical and histopathological features. An overview of most common phenotypes and of possible complications is given. The management of the main clinical respiratory, cardiac, and central nervous system complications are covered. The instrumental, muscle imaging, and laboratory exams to assess and reach diagnosis are described. The use of recent genetic techniques such as next generation sequencing (NGS), whole-exome sequencing compared to other techniques (e.g. DNA sequencing, protein analysis) is covered. Currently available drugs or gene therapy and rehabilitation management are focused on. Expert commentary: Many LGMD cases, which for a long time previously remained without a molecular diagnosis, can now be investigated by NGS. Gene mutation analysis is always required to obtain a certain molecular diagnosis, fundamental to select homogeneous group of patients for future pharmaceutical and gene trials.

AB - Introduction: Limb-girdle muscular dystrophies (LGMDs) encompass a clinically heterogeneous group of rare, genetic progressive muscle disorders presenting with weakness and atrophy of predominant pelvic and shoulder muscles. The spectrum of disease severity ranges from severe childhood-onset muscular dystrophy to adult-onset dystrophy. Areas covered: The review presents an update of the clinical phenotypes and diagnostic options for LGMD including both dominant and recessive LGMD and consider their differential clinical and histopathological features. An overview of most common phenotypes and of possible complications is given. The management of the main clinical respiratory, cardiac, and central nervous system complications are covered. The instrumental, muscle imaging, and laboratory exams to assess and reach diagnosis are described. The use of recent genetic techniques such as next generation sequencing (NGS), whole-exome sequencing compared to other techniques (e.g. DNA sequencing, protein analysis) is covered. Currently available drugs or gene therapy and rehabilitation management are focused on. Expert commentary: Many LGMD cases, which for a long time previously remained without a molecular diagnosis, can now be investigated by NGS. Gene mutation analysis is always required to obtain a certain molecular diagnosis, fundamental to select homogeneous group of patients for future pharmaceutical and gene trials.

KW - calpainopathy

KW - dysferlinopathy

KW - Limb-girdle muscular dystrophy

KW - sarcoglycanopathy

KW - transportinopathy

UR - http://www.scopus.com/inward/record.url?scp=85052934981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052934981&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1508997

DO - 10.1080/14737175.2018.1508997

M3 - Review article

AN - SCOPUS:85052934981

VL - 18

SP - 693

EP - 703

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 9

ER -